Cited by 1,858HER2/EGFR in Cancer ResearchPI3K/AKT/mTOR signaling in cancerBreast Cancer Treatment Studies

The DOI matches its Crossref record; 65 of the 70 references it cites were found in a registry or an index.

PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients

Open access

Nagata, Yoichi, Lan, Keng-Hsueh, Zhou, Xiaoyan, Tan, Ming, Esteva, Francisco J., Sahin, Aysegul A., Klos, Kristine S., Li, Ping, Monia, Brett P., Nguyen, Nina T., Hortobagyi, Gabriel N., Hung, Mien-Chie, Yu, Dihua·2004·Cancer Cell

DOI 10.1016/j.ccr.2004.06.022

Open this paper in CoChat — free account Open PDF

Abstract

The ErbB2-targeting antibody, trastuzumab (Herceptin), has remarkable therapeutic efficacy in certain patients with ErbB2-overexpressing tumors. The overall trastuzumab response rate, however, is limited and what determines trastuzumab response is poorly understood. Here we report that PTEN activation contributes to trastuzumab's antitumor activity. Trastuzumab treatment quickly increased PTEN membrane localization and phosphatase activity by reducing PTEN tyrosine phosphorylation via Src inhibition. Reducing PTEN in breast cancer cells by antisense oligonucleotides conferred trastuzumab resistance in vitro and in vivo. Patients with PTEN-deficient breast cancers had significantly poorer responses to trastuzumab-based therapy than those with normal PTEN. Thus, PTEN deficiency is a powerful predictor for trastuzumab resistance. Additionally, PI3K inhibitors rescued PTEN loss-induced trastuzumab resistance, suggesting that PI3K-targeting therapies could overcome this resistance.

Integrity signals

Registry

Crossref · 10.1016/j.ccr.2004.06.022

Cites

65 of 65 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu Oncogene
Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., & McGuire, W. L. (1987) · Science · doi:10.1126/science.3798106 · Cited by 11,760
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500
The phosphoinositide 3-kinase pathway
Cantley, L. C. (2002) · Science · doi:10.1126/science.296.5573.1655 · Cited by 5,621
PTEN , a Putative Protein Tyrosine Phosphatase Gene Mutated in Human Brain, Breast, and Prostate Cancer
Li, J., Yen, C., Liaw, D., Podsypanina, K., Bose, S., Wang, S. I., Puc, J., Miliaresis, C., Rodgers, L., McCombie, R., et al. (1997) · Science · doi:10.1126/science.275.5308.1943 · Cited by 4,785
Multinational Study of the Efficacy and Safety of Humanized Anti-HER2 Monoclonal Antibody in Women Who Have HER2-Overexpressing Metastatic Breast Cancer That Has Progressed After Chemotherapy for Metastatic Disease
Cobleigh, M., Vogel, C. L., Tripathy, D., Robert, N. J., Scholl, S., Fehrenbacher, L., Wolter, J. M., Paton, V. E., Shak, S., Lieberman, G., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.9.2639 · Cited by 2,767
New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway
Cantley, L. C., & Neel, B. G. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.8.4240 · Cited by 2,018
Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of HER2-Overexpressing Metastatic Breast Cancer
Vogel, C. L., Cobleigh, M. A., Tripathy, D., Gutheil, J. C., Harris, L. N., Fehrenbacher, L., Slamon, D. J., Murphy, M., Novotny, W. F., Burchmore, M., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.20.3.719 · Cited by 1,860
Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab
Cho, H., Mason, K., Ramyar, K. X., Stanley, A. M., Gabelli, S. B., Denney, D. W., & Leahy, D. J. (2003) · Nature · doi:10.1038/nature01392 · Cited by 1,637
The Multiple Roles of PTEN in Tumor Suppression
Di Cristofano, A., & Pandolfi, P. P. (2000) · Cell · doi:10.1016/s0092-8674(00)80674-1 · Cited by 1,182
Insulin-Like Growth Factor-I Receptor Signaling and Resistance to Trastuzumab (Herceptin)
Lu, Y., Zi, X., Zhao, Y., Mascarenhas, D. D., & Pollak, M. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.24.1852 · Cited by 886

Flagged first, then by citations

Show all 70 references

5 of the 70 references couldn’t be matched to a known paper.

Research works printed but not linked: 1

Petit, 1997, Neutralizing antibodies against epidermal growth factor and ErbB2/neu receptor tyrosine kinase down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo, Am. J. Pathol., 151, 1523

Sorted by citations

Items 301–400 of 1,001

Acquired resistance to drugs targeting receptor tyrosine kinases
Rosenzweig, S. A. (2011) · Biochemical Pharmacology · doi:10.1016/j.bcp.2011.12.025 · Cited by 122
Everolimus
Hasskarl, J. (2018) · Recent results in cancer research/Recent Results in Cancer Research · doi:10.1007/978-3-319-91442-8_8 · Cited by 129
Role of the HER2 [Ile655Val] genetic polymorphism in tumorogenesis and in the risk of trastuzumab-related cardiotoxicity
Beauclair, S., Formento, P., Fischel, J., Lescaut, W., Largillier, R., Chamorey, E., Hofman, P. M., Ferrero, J.-M., Pagès, G., & Milano, G. A. (2007) · Annals of Oncology · doi:10.1093/annonc/mdm181 · Cited by 121
Prognostic and Predictive Implications of PTEN in Breast Cancer: Unfulfilled Promises but Intriguing Perspectives
Carbognin, L., Miglietta, F., Paris, I., & Dieci, M. V. (2019) · Cancers · doi:10.3390/cancers11091401 · Cited by 121
Overcoming trastuzumab resistance in HER2‐positive breast cancer using combination therapy
Derakhshani, A., Rezaei, Z., Safarpour, H., Sabri, M., Mir, A., Sanati, M. A., Vahidian, F., Moghadam, A. G., Aghadoukht, A., Hajiasgharzadeh, K., et al. (2019) · Journal of Cellular Physiology · doi:10.1002/jcp.29216 · Cited by 128
Correction: HER2 Phosphorylation Is Maintained by a PKB Negative Feedback Loop in Response to Anti-HER2 Herceptin in Breast Cancer
Gijsen, M., King, P., Perera, T., Parker, P. J., Harris, A. L., Larijani, B., & Kong, A. H. (2016) · PLoS Biology · doi:10.1371/journal.pbio.1002414 · Cited by 120
Targeting PI3K/mTOR Overcomes Resistance to HER2-Targeted Therapy Independent of Feedback Activation of AKT
O’Brien, N. A., McDonald, K., Luo, T., von Euw, E., Kalous, O., Conklin, D. F., Hurvitz, S. A., di Tomaso, E., Schnell, C., Linnartz, R., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2769 · Cited by 122
Molecular Mechanisms of Trastuzumab Resistance in HER2 Overexpressing Breast Cancer
Fiszman, G. L., & Jasnis, M. A. (2011) · International Journal of Breast Cancer · doi:10.4061/2011/352182 · Cited by 119
Lapatinib monotherapy in patients with HER2-overexpressing relapsed or refractory inflammatory breast cancer: final results and survival of the expanded HER2+ cohort in EGF103009, a phase II study
Kaufman, B., Trudeau, M., Awada, A. H., Blackwell, K., Bachelot, T., Salazar, V., DeSilvio, M., WESTLUND, R. E., Zaks, T. Z., Spector, N. L., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70087-7 · Cited by 119
Gefitinib-Sensitive Mutations of the Epidermal Growth Factor Receptor Tyrosine Kinase Domain in Chinese Patients with Non–Small Cell Lung Cancer
Mu, X. L., Li, L. Y., Zhang, X. T., Wang, M. Z., Feng, R. E., Cui, Q. C., Zhou, H., & Guo, B. Q. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2506 · Cited by 118
Ontogeny and Vulnerabilities of Drug-Tolerant Persisters in HER2+ Breast Cancer
Chang, C. A., Jen, J., Jiang, S., Sayad, A., Mer, A. S., Brown, K. R., Nixon, A. M. L., Dhabaria, A., Tang, K. H., Venet, D., et al. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1265 · Cited by 119
A genomic explanation connecting “Mediterranean diet”, olive oil and cancer: Oleic acid, the main monounsaturated Fatty acid of olive oil, induces formation of inhibitory “PEA3 transcription factor-PEA3 DNA binding site” complexes at the Her-2/neu (erbB-2) oncogene promoter in breast, ovarian and stomach cancer cells
Menéndez, J. A., Papadimitropoulou, A., Vellón, L., & Lupu, R. (2006) · European Journal of Cancer · doi:10.1016/j.ejca.2005.10.016 · Cited by 117
Loss of RALT/MIG-6 expression in ERBB2-amplified breast carcinomas enhances ErbB-2 oncogenic potency and favors resistance to Herceptin
Anastasi, S., Sala, G., Huiping, C., Caprini, E., Russo, G., Iacovelli, S., Lucini, F., Ingvarsson, S., & Segatto, O. (2005) · Oncogene · doi:10.1038/sj.onc.1208658 · Cited by 115
Signaling cross-talk in the resistance to HER family receptor targeted therapy
Yamaguchi, H., Chang, S. H., Hsu, J. L., & Hung, M. (2013) · Oncogene · doi:10.1038/onc.2013.74 · Cited by 118
HER-2-Targeted Nanoparticles for Breast Cancer Diagnosis and Treatment
Sitia, L., Sevieri, M., Signati, L., Bonizzi, A., Chesi, A., Mainini, F., Corsi, F., & Mazzucchelli, S. (2022) · Cancers · doi:10.3390/cancers14102424 · Cited by 122
Mechanisms of resistance to anti‐human epidermal growth factor receptor 2 agents in breast cancer
Mukohara, T. (2010) · Cancer Science · doi:10.1111/j.1349-7006.2010.01711.x · Cited by 113
Adipose cells promote resistance of breast cancer cells to trastuzumab-mediated antibody-dependent cellular cytotoxicity
Duong, M. N., Cleret, A., Matera, E., Chettab, K., Mathé, D., Valsesia‐Wittmann, S., Clemenceau, B., & Dumontet, C. (2015) · Breast Cancer Research · doi:10.1186/s13058-015-0569-0 · Cited by 115
Acquired Resistance to Small Molecule ErbB2 Tyrosine Kinase Inhibitors
Chen, F. L., Xia, W., & Spector, N. L. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0581 · Cited by 114
Cancer targeted therapeutics: From molecules to drug delivery vehicles
Liu, D., & Auguste, D. T. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.08.041 · Cited by 113
PRKACA mediates resistance to HER2-targeted therapy in breast cancer cells and restores anti-apoptotic signaling
Moody, S. E., Schinzel, A. C., Singh, S., Izzo, F., Strickland, M. R., Luo, L. Y., Thomas, S. R., Boehm, J. S., Kim, S. Y., Wang, Z. C., et al. (2014) · Oncogene · doi:10.1038/onc.2014.153 · Cited by 110
Activity of lapatinib a novel HER2 and EGFR dual kinase inhibitor in human endometrial cancer cells
Konecny, G. E., Venkatesan, N., Yang, G., Dering, J., Ginther, C., Finn, R. S., Rahmeh, M., Fejzo, M. S., Toft, D. O., Jiang, S.-W., et al. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604278 · Cited by 112
Evolving novel anti-HER2 strategies
Jones, K. L., & Buzdar, A. U. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70315-8 · Cited by 112
Targeted therapies: how personal should we go?
Martini, M., Vecchione, L., Siena, S., Tejpar, S., & Bardelli, A. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2011.164 · Cited by 112
Trastuzumab
Garnock-Jones, K. P., Keating, G. M., & Scott, L. J. (2010) · Drugs · doi:10.2165/11203700-000000000-00000 · Cited by 114
Multiple molecular mechanisms underlying trastuzumab and lapatinib resistance in JIMT-1 breast cancer cells
Köninki, K., Barok, M., Tanner, M., Staff, S. M., Pitkänen, J., Hemmilä, P., Ilvesaro, J. M., & Isola, J. J. (2010) · Cancer Letters · doi:10.1016/j.canlet.2010.02.002 · Cited by 112
Testican-1-mediated epithelial–mesenchymal transition signaling confers acquired resistance to lapatinib in HER2-positive gastric cancer
Kim, H.-P., Han, S.-W., Song, S., Jeong, E.-G., Lee, M.-Y., Hwang, D., Im, S., Bang, Y.-J., & Kim, T.-Y. (2013) · Oncogene · doi:10.1038/onc.2013.285 · Cited by 110
The Phosphoinositide-3-Kinase-Akt-mTOR Pathway as a Therapeutic Target in Breast Cancer
Lauring, J. D., Park, B. H., & Wolff, A. C. (2013) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2013.0086 · Cited by 114
Folic acid conjugated polymeric micelles loaded with a curcumin difluorinated analog for targeting cervical and ovarian cancers
Luong, D., Kesharwani, P., Alsaab, H. O., Sau, S., Padhyé, S., Sarkar, F. H., & Iyer, A. K. (2017) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2017.06.025 · Cited by 113
Molecular intrinsic versus clinical subtyping in breast cancer: A comprehensive review
Szymiczek, A., Lone, A., & Akbari, M. R. (2020) · Clinical Genetics · doi:10.1111/cge.13900 · Cited by 120
Tumour suppressor genes in chemotherapeutic drug response
Lai, D., Grieve, S., & Yang, X. (2012) · Bioscience Reports · doi:10.1042/bsr20110125 · Cited by 110
Notch-1-PTEN-ERK1/2 signaling axis promotes HER2+ breast cancer cell proliferation and stem cell survival
Baker, A. T., Wyatt, D. L., Bocchetta, M., Li, J., Filipović, A., Green, A. R., Peiffer, D. S., Fuqua, S. A. W., Miele, L., Albain, K. S., et al. (2018) · Oncogene · doi:10.1038/s41388-018-0251-y · Cited by 108
Unraveling the Biologic and Clinical Complexities of HER2
Park, J. W., Neve, R. M., Szöllõsi, J., & Benz, C. C. (2008) · Clinical Breast Cancer · doi:10.3816/cbc.2008.n.047 · Cited by 109
Mediterranean diet, olive oil and cancer
Colomer, R., & Menéndez, J. A. (2006) · Clinical & Translational Oncology · doi:10.1007/s12094-006-0090-0 · Cited by 109
Vorinostat interferes with the signaling transduction pathway of T-cell receptor and synergizes with phosphoinositide-3 kinase inhibitors in cutaneous T-cell lymphoma
Wozniak, M. B., Villuendas, R., Bischoff, J. R., Aparicio, C. B., Martínez-Leal, J. F., de la Cueva, P., Rodríguez, M. E., Herreros, B., Martín-Pérez, D., Longo, M. I., et al. (2010) · Haematologica · doi:10.3324/haematol.2009.013870 · Cited by 108
EGFR/HER2 in breast cancer: a biological approach for molecular diagnosis and therapy
Milanezi, F., Carvalho, S., & Schmitt, F. C. (2008) · Expert Review of Molecular Diagnostics · doi:10.1586/14737159.8.4.417 · Cited by 109
Targeting the MUC1-C oncoprotein downregulates HER2 activation and abrogates trastuzumab resistance in breast cancer cells
Raina, D. B., Uchida, Y., Kharbanda, A., Rajabi, H. N., Panchamoorthy, G., Jin, C., Kharbanda, S. M., Scaltriti, M., Baselga, J. M., & Kufe, D. W. (2013) · Oncogene · doi:10.1038/onc.2013.308 · Cited by 108
A serum microRNA signature predicts trastuzumab benefit in HER2-positive metastatic breast cancer patients
Li, H., Liu, J., Chen, J., Wang, H., Yang, L., Chen, F., Fan, S., Wang, J., Shao, B., Yin, D., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-03537-w · Cited by 107
Impact of PTEN protein expression on benefit from adjuvant trastuzumab in early-stage human epidermal growth factor receptor 2-positive breast cancer in the North Central Cancer Treatment Group N9831 trial
Perez, E. A., Dueck, A. C., McCullough, A. E., Chen, B., Geiger, X. J., Jenkins, R. B., Lingle, W. L., Davidson, N. E., Martino, S., Kaufman, P. A., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.42.2642 · Cited by 106
The impact of tumor stroma on drug response in breast cancer
Dittmer, J., & Leyh, B. (2014) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2014.05.006 · Cited by 107
Trastuzumab Emtansine (T-DM1): A Novel Agent for Targeting HER2+ Breast Cancer
Burris, H. A., Tibbitts, J., Holden, S. N., Sliwkowski, M. X., & Phillips, G. D. L. (2011) · Clinical Breast Cancer · doi:10.1016/j.clbc.2011.03.018 · Cited by 106
A phase 1 study evaluating the combination of an allosteric AKT inhibitor (MK-2206) and trastuzumab in patients with HER2-positive solid tumors
Hudis, C. A., Swanton, C., Janjigian, Y. Y., Lee, R., Sutherland, S., Lehman, R. J., Chandarlapaty, S., Hamilton, N., Gajria, D., Knowles, J., et al. (2013) · Breast Cancer Research · doi:10.1186/bcr3577 · Cited by 106
Recombinant Human Insulin-like Growth Factor Binding Protein 3 Inhibits Growth of Human Epidermal Growth Factor Receptor-2–Overexpressing Breast Tumors and Potentiates Herceptin Activity In vivo
Jerome, L., Alami, N., Belanger, S., Pagé, V., Yu, Q., Paterson, J., Shiry, L., Pegram, M. D., & Leyland-Jones, B. R. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3555 · Cited by 106
Resistance to EGF receptor inhibitors in glioblastoma mediated by phosphorylation of the PTEN tumor suppressor at tyrosine 240
Fenton, T. R., Nathanson, D. A., de Albuquerque, C. P., Kuga, D., Iwanami, A., Dang, J. H. T., Yang, H., Tanaka, K., Oba‐Shinjo, S. M., Uno, M., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1211962109 · Cited by 106
HER2-positive advanced breast cancer: optimizing patient outcomes and opportunities for drug development
Singh, J. C., Jhaveri, K. L., & Esteva, F. J. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.388 · Cited by 106
Use of molecular markers for predicting therapy response in cancer patients
Duffy, M. J., O’Donovan, N., & Crown, J. P. (2010) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2010.07.004 · Cited by 107
Breast Cancer Stem Cells: Current Advances and Clinical Implications
Luo, M., Clouthier, S. G., Deol, Y. S., Liu, S., Nagrath, S., Azizi, E., & Wicha, M. S. (2015) · Methods in molecular biology · doi:10.1007/978-1-4939-2519-3_1 · Cited by 106
Should individual PI3 kinase isoforms be targeted in cancer?
Jia, S., Roberts, T. M., & Zhao, J. J. (2009) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2008.12.007 · Cited by 107
Prognostic vs predictive molecular biomarkers in colorectal cancer: is KRAS and BRAF wild type status required for anti-EGFR therapy?
Rizzo, S., Bronte, G., Fanale, D., Corsini, L. R., Silvestris, N., Santini, D., Gulotta, G., Bazan, V., Gebbia, N., Fulfaro, F., et al. (2010) · Cancer Treatment Reviews · doi:10.1016/s0305-7372(10)70021-9 · Cited by 165
Targeting the Akt Kinase to Modulate Survival, Invasiveness and Drug Resistance of Cancer Cells
Cassinelli, G., Zuco, V., Gatti, L., Lanzi, C., Zaffaroni, N., Colombo, D., & Perego, P. (2013) · Current Medicinal Chemistry · doi:10.2174/09298673113209990106 · Cited by 104
Acquisition of resistance to trastuzumab in gastric cancer cells is associated with activation of IL-6/STAT3/Jagged-1/Notch positive feedback loop
Yang, Z., Guo, L., Liu, D., Sun, L., Chen, H., Deng, Q., Liu, Y., Yu, M., Yuan-fang Ma, A., Guo, N., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.3241 · Cited by 101
HER2 Status in High-Risk Endometrial Cancers (PORTEC-3): Relationship with Histotype, Molecular Classification, and Clinical Outcomes
Vermij, L., Horeweg, N., León‐Castillo, A., Rutten, T. A., Mileshkin, L., MacKay, H. J., Leary, A. F., Powell, M. E. B., Singh, N., Crosbie, E. J., et al. (2020) · Cancers · doi:10.3390/cancers13010044 · Cited by 104
Antibody-Drug Conjugates for the Treatment of HER2-Positive Breast Cancer
Najjar, M. K., Manore, S. G., Regua, A. T., & Lo, H. (2022) · Genes · doi:10.3390/genes13112065 · Cited by 110
The MicroRNA-21/PTEN Pathway Regulates the Sensitivity of HER2-Positive Gastric Cancer Cells to Trastuzumab
Eto, K., Iwatsuki, M., Watanabe, M., Ida, S., Ishimoto, T., Iwagami, S., Baba, Y., Sakamoto, Y., Miyamoto, Y., Yoshida, N., et al. (2013) · Annals of Surgical Oncology · doi:10.1245/s10434-013-3325-7 · Cited by 103
Upregulation and activation of PKCα by ErbB2 through Src promotes breast cancer cell invasion that can be blocked by combined treatment with PKCα and Src inhibitors
Tan, M., Li, P., Sun, M.-E., Yin, G., & Yu, D.-H. (2006) · Oncogene · doi:10.1038/sj.onc.1209361 · Cited by 114
mTOR as a therapeutic target in patients with gastric cancer
Al-Batran, S. E., Ducreux, M. P., & Ohtsu, A. (2011) · International Journal of Cancer · doi:10.1002/ijc.26396 · Cited by 101
Pregnane X receptor mediates sorafenib resistance in advanced hepatocellular carcinoma
Feng, F., Jiang, Q., Cao, S., Cao, Y. W., Li, R., Shen, L., Zhu, H., Wang, T., Sun, L., Liang, E., et al. (2018) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2018.01.011 · Cited by 102
H1047R phosphatidylinositol 3-kinase mutant enhances HER2-mediated transformation by heregulin production and activation of HER3
Chakrabarty, A., Rexer, B. N., Wang, S. E., Cook, R. S., Engelman, J. A., & Arteaga, C. L. (2010) · Oncogene · doi:10.1038/onc.2010.257 · Cited by 102
Relationship between tumor biomarkers and efficacy in TH3RESA, a phase III study of trastuzumab emtansine (T‐DM1) vs. treatment of physician's choice in previously treated HER2‐positive advanced breast cancer
Kim, S., Wildiers, H. P. M. W., Krop, I. E., Smitt, M. C., Yu, R., de Haas, S. L., & González-Martı́n, A. (2016) · International Journal of Cancer · doi:10.1002/ijc.30276 · Cited by 101
Dual Blockade of HER2 in HER2-Overexpressing Tumor Cells Does Not Completely Eliminate HER3 Function
Garrett, J. T., Sutton, C. R., Kuba, M. G., Cook, R. S., & Arteaga, C. L. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2024 · Cited by 99
Defining biomarkers to predict sensitivity to PI3K/Akt/mTOR pathway inhibitors in breast cancer
Gonzalez-Angulo, A. M., & Blumenschein, G. R. (2012) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2012.11.002 · Cited by 101
PTEN expression is upregulated by a RNA-binding protein RBM38 via enhancing its mRNA stability in breast cancer
Zhou, S., Wu, J., Shi, L., Li, X., Zhu, L., Sun, X., Qian, J., Wang, Y., Wei, J., & Ding, Q. (2017) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-017-0620-3 · Cited by 98
Low PTEN levels and PIK3CA mutations predict resistance to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2 over-expressing breast cancer
Rimawi, M. F., Angelis, C. D., Contreras, A., Pareja, F. G., Geyer, F. C., Burke, K. A., Herrera, S., Wang, T., Mayer, I. A., Forero, A., et al. (2017) · Breast Cancer Research and Treatment · doi:10.1007/s10549-017-4533-9 · Cited by 98
A novel inhibitor of fatty acid synthase shows activity against HER2+ breast cancer xenografts and is active in anti-HER2 drug-resistant cell lines
Puig, T., Aguilar, H., Cufí, S., Oliveras, G., Turrado, C., Ortega‐Gutiérrez, S., Benhamú, B., López-Rodríguez, M. L., Urruticoechea, A., & Colomer, R. (2011) · Breast Cancer Research · doi:10.1186/bcr3077 · Cited by 100
HER2 Protein and Gene Variation between Primary and Metastatic Breast Cancer: Significance and Impact on Patient Care
Fabi, A., Benedetto, A. D., Metro, G., Perracchio, L., Nisticò, C., Filippo, F. D., Ercolani, C., Ferretti, G., Melucci, E., Buglioni, S., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1920 · Cited by 97
Protein tyrosine phosphatases: dual‐specificity phosphatases in health and disease
Pulido, R., & van Huijsduijnen, R. H. (2008) · FEBS Journal · doi:10.1111/j.1742-4658.2008.06250.x · Cited by 97
Overexpression of 14-3-3ζ in cancer cells activates PI3K via binding the p85 regulatory subunit
Neal, C. L., Xu, J., Li, P., Mori, S., Yang, J. D., Neal, N. N., Zhou, X., Wyszomierski, S. L., & Yu, D. (2011) · Oncogene · doi:10.1038/onc.2011.284 · Cited by 97
The Nuclear Receptor Coactivator Amplified in Breast Cancer-1 Is Required for Neu (ErbB2/HER2) Activation, Signaling, and Mammary Tumorigenesis in Mice
Fereshteh, M., Tilli, M. T., Kim, S. E., Xu, J., O’Malley, B. W., Wellstein, A., Furth, P. A., & Riegel, A. T. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6702 · Cited by 98
Prognostic and predictive biomarkers for epidermal growth factor receptor-targeted therapy in colorectal cancer: Beyond KRAS mutations
Custodio, A., & Feliú, J. (2012) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2012.05.001 · Cited by 100
Evolving Strategies for Overcoming Resistance to HER2-Directed Therapy: Targeting the PI3K/Akt/mTOR Pathway
Nahta, R., & O'Regan, R. M. (2010) · Clinical Breast Cancer · doi:10.3816/cbc.2010.s.015 · Cited by 95
β2-AR signaling controls trastuzumab resistance-dependent pathway
Liu, D., Yang, Z., Wang, T., Yang, Z., Chen, H., Hu, Y., Hu, C., Guo, L., Deng, Q., Liu, Y., et al. (2015) · Oncogene · doi:10.1038/onc.2015.58 · Cited by 97
Src, a potential target for overcoming trastuzumab resistance in HER2-positive breast carcinoma
Peiró, G., Ortiz-Martínez, F., Gallardo, A., Perez‐Balaguer, A., Sánchez–Payá, J., Ponce, J., Tibau, A., López-Vilaró, L., Escuín, D., Adrover, E., et al. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.327 · Cited by 95
The combination of trastuzumab and pertuzumab administered at approved doses may delay development of trastuzumab resistance by additively enhancing antibody-dependent cell-mediated cytotoxicity
Tóth, G., Szöőr, Á., Simon, L., Yarden, Y., Szöllõsi, J., & Vereb, G. (2016) · mAbs · doi:10.1080/19420862.2016.1204503 · Cited by 94
Tumor suppressor PTEN in breast cancer: heterozygosity, mutations and protein expression.
Kechagioglou, P., Papi, R. M., Provatopoulou, X., Kalogera, E., Papadimitriou, E., Grigoropoulos, P., Nonni, A., Zografos, G., Kyriakidis, D. A., & Gounaris, A. (2014) · PubMed · Cited by 95
p85 Associates with Unphosphorylated PTEN and the PTEN-Associated Complex
Rabinovsky, R., Pochanard, P., McNear, C. J., Brachmann, S. M., Duke‐Cohan, J. S., Garraway, L. A., & Sellers, W. R. (2009) · Molecular and Cellular Biology · doi:10.1128/mcb.01649-08 · Cited by 92
Acquired Resistance to Drugs Targeting Tyrosine Kinases
Rosenzweig, S. A. (2018) · Advances in cancer research · doi:10.1016/bs.acr.2018.02.003 · Cited by 93
Enhancement of the Therapeutic Efficacy of Taxol by the Mitogen-Activated Protein Kinase Kinase Inhibitor CI-1040 in Nude Mice Bearing Human Heterotransplants
McDaid, H. M., Lopez-Barcons, L. A., Grossman, A., Lia, M., Keller, S. M., Perez-Soler, R., & Horwitz, S. B. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-4391 · Cited by 94
Trastuzumab and breast cancer: developments and current status
Tokunaga, E., Oki, E., Nishida, K., Koga, T., Egashira, A., Morita, M., Kakeji, Y., & Maehara, Y. (2006) · International Journal of Clinical Oncology · doi:10.1007/s10147-006-0575-4 · Cited by 94
Genetic and epigenetic contribution to astrocytic gliomas pathogenesis
Khani, P., Nasri, F., Chamani, F. K., Saeidi, F., Nahand, J. S., Tabibkhooei, A., & Mirzaei, H. (2018) · Journal of Neurochemistry · doi:10.1111/jnc.14616 · Cited by 94
Role of c-Src in Human MCF7 Breast Cancer Cell Tumorigenesis
González, L., Agulló-Ortuño, M. T., García-Martínez, J. M., Calcabrini, A., Gamallo, C., Palacios, J., Aranda, A., & Martı́n-Pérez, J. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m601570200 · Cited by 95
Her2 cross talk and therapeutic resistance in breast cancer
Laura, M. B. (2008) · Frontiers in bioscience · doi:10.2741/2978 · Cited by 93
Profile of neratinib and its potential in the treatment of breast cancer
Kong, A. H., & Feldinger, K. (2015) · Breast Cancer Targets and Therapy · doi:10.2147/bctt.s54414 · Cited by 99
Beyond Trastuzumab: Small Molecule Tyrosine Kinase Inhibitors in HER-2–Positive Breast Cancer
Roy, V., & Perez, E. A. (2009) · The Oncologist · doi:10.1634/theoncologist.2009-0142 · Cited by 92
Intrinsic and acquired resistance to EGFR inhibitors in human cancer therapy
Bianco, R., Troiani, T., Tortora, G., & Ciardiello, F. (2005) · Endocrine Related Cancer · doi:10.1677/erc.1.00999 · Cited by 92
The sensitivity of gastric cancer to trastuzumab is regulated by the mi R ‐223/ FBXW 7 pathway
Eto, K., Iwatsuki, M., Watanabe, M., Ishimoto, T., Ida, S., Imamura, Y., Iwagami, S., Baba, Y., Sakamoto, Y., Miyamoto, Y., et al. (2014) · International Journal of Cancer · doi:10.1002/ijc.29168 · Cited by 93
Current Therapies for Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer Patients
Larionov, A. A. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00089 · Cited by 95
Overcoming resistance to molecularly targeted anticancer therapies: Rational drug combinations based on EGFR and MAPK inhibition for solid tumours and haematologic malignancies
Tortora, G., Bianco, R., Daniele, G., Ciardiello, F., McCubrey, J. A., Ricciardi, M. R., Ciuffreda, L., Cognetti, F., Tafuri, A., & Milella, M. (2007) · Drug Resistance Updates · doi:10.1016/j.drup.2007.03.003 · Cited by 91
Inflammation and IGF‐I activate the Akt pathway in breast cancer
Prueitt, R. L., Boersma, B. J., Howe, T. M., Goodman, J. E., Thomas, D. D., Lei, Y., Pfiester, C. M., Yfantis, H. G., Cottrell, J. R., Lee, D. H., et al. (2006) · International Journal of Cancer · doi:10.1002/ijc.22336 · Cited by 91
PTEN Expression in Melanoma: Relationship with Patient Survival, Bcl-2 Expression, and Proliferation
Mikhail, M., Velazquez, E., Shapiro, R. L., Berman, R. S., Pavlick, A. C., Sorhaindo, L., Spira, J., Mir, C. M., Panageas, K. S., Polsky, D., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0397 · Cited by 89
Overcoming resistance and restoring sensitivity to HER2-targeted therapies in breast cancer
Sharial, M. S. N. M., Crown, J. P., & Hennessy, B. T. (2012) · Annals of Oncology · doi:10.1093/annonc/mds200 · Cited by 90
Beyond trastuzumab: novel therapeutic strategies in HER2-positive metastatic breast cancer
Tsang, R. Y., & Finn, R. S. (2012) · British Journal of Cancer · doi:10.1038/bjc.2011.516 · Cited by 90
Safety, Efficacy, and Biomarker Analysis of Pyrotinib in Combination with Capecitabine in HER2-Positive Metastatic Breast Cancer Patients: A Phase I Clinical Trial
Li, Q., Guan, X., Chen, S., Yi, Z., Lan, B., Xing, P., Fan, Y., Wang, J., Luo, Y., Yuan, P., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-4173 · Cited by 91
Critical role of PTEN in the coupling between PI3K/Akt and JNK1/2 signaling in ischemic brain injury
Zhang, Q., Dong-na, W. U., Han, D. K., & Zhang, G. (2007) · FEBS Letters · doi:10.1016/j.febslet.2006.12.055 · Cited by 90
Therapeutic Antibodies Against Cancer
Adler, M. J., & Dimitrov, D. S. (2012) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2012.02.013 · Cited by 94
Involvement of Akt and mTOR in chemotherapeutic- and hormonal-based drug resistance and response to radiation in breast cancer cells
Steelman, L. S., Navolanic, P. M., Chappell, W. H., Abrams, S. L., Wong, E. W. T., Martelli, A. M., Cocco, L., Stivala, F., Libra, M., Nicoletti, F., et al. (2011) · Cell Cycle · doi:10.4161/cc.10.17.17119 · Cited by 88
Evolution of anti-HER2 therapies for cancer treatment
Parakh, S., Gan, H. K., Parslow, A. C., Burvenich, I. J. G., Burgess, A. W., & Scott, A. M. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.06.005 · Cited by 89
Mining the Tumor Phosphoproteome for Cancer Markers
Lim, Y. P. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2243 · Cited by 88
β1-Integrin Circumvents the Antiproliferative Effects of Trastuzumab in Human Epidermal Growth Factor Receptor-2–Positive Breast Cancer
Lesniak, D. M., Xu, Y., Deschênes, J., Lai, R. L., Thoms, J., Murray, D., Gosh, S., Mackey, J. R., Sabri, S., & Abdulkarim, B. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-1591 · Cited by 91
Rac1 contributes to trastuzumab resistance of breast cancer cells: Rac1 as a potential therapeutic target for the treatment of trastuzumab-resistant breast cancer
Dokmanovic, M., Hirsch, D. S., Shen, Y., & Wu, W. J. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0140 · Cited by 90
ADAM10 mediates trastuzumab resistance and is correlated with survival in HER2 positive breast cancer
Feldinger, K., Generali, D., Krämer-Marek, G., Gijsen, M., Ng, T. B., Wong, J. H., Strina, C., Cappelletti, M., Andreis, D., Li, J., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.1955 · Cited by 88
Evaluating the predictive value of biomarkers for efficacy outcomes in response to pertuzumab- and trastuzumab-based therapy: an exploratory analysis of the TRYPHAENA study
Schneeweiß, A., Chia, S., Hegg, R., Tausch, C., Deb, R., Ratnayake, J., McNally, V. A., Ross, G. A., Kiermaier, A. C., & Cortés, J. (2014) · Breast Cancer Research · doi:10.1186/bcr3690 · Cited by 88

Authors: Nagata, Y., Lan, K.-H., Zhou, X., Tan, M., Esteva, F. J., Sahin, A. A., Klos, K. S., Li, P., Monia, B. P., Nguyen, N. T., Hortobagyi, G. N., Hung, M.-C., & Yu, D.
Affiliations: The University of Texas MD Anderson Cancer Center (US)
Ionis Pharmaceuticals (United States) (US)
Corresponding author: Yu, Dihua
ORCID: Lan, Keng-Hsueh
Zhou, Xiaoyan
Tan, Ming
Esteva, Francisco J.
Li, Ping
Monia, Brett P.
Hung, Mien-Chie
Yu, Dihua
Venue: Cancer Cell
Publisher: Elsevier BV
Published: 2004-08
Volume: 6
Issue: 2
Pages: 117-127
ISSN: 1535-6108 (ISSN-L)
DOI: 10.1016/j.ccr.2004.06.022
OpenAlex: W2059411043
Cited by: 1,858
References: 70
Citations by year: 2026: 19 · 2025: 29 · 2024: 35 · 2023: 82 · 2022: 52 · 2021: 50 · 2020: 60 · 2019: 56 · 2018: 66 · 2017: 68 · 2016: 88 · 2015: 109 · 2014: 119 · 2013: 125 · 2012: 123
FWCI: 43.34
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/open-access/userlicense/1.0/ (vor, 3272 d)
Locations: Cancer Cell (publishedVersion)
PubMed (publishedVersion)
Funders: National Institutes of Health (5r01ca060488-09)
National Cancer Institute (P01CA099031, 2R01-CA60488, P30CA016672)
Topics: Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
Keywords: PTEN, trastuzumab, trastuzumab resistance, ERBB2, HER2-positive breast cancer, Src kinase inhibition, PI3K inhibitors, predictive biomarkers, antisense oligonucleotides
MeSH terms: Trastuzumab, Phosphoinositide-3 Kinase Inhibitors, Animals, Antibodies, Monoclonal, Antineoplastic Agents, Breast Neoplasms, Enzyme Activation, Enzyme Inhibitors, Female, Humans, Mice, Nude, Neoplasm Transplantation, Phosphoric Monoester Hydrolases, Proto-Oncogene Proteins, Genes, Tumor Suppressor, Oligonucleotides, Antisense, Protein Serine-Threonine Kinases, Erb-b2 Receptor Tyrosine Kinases, Drug Resistance, Neoplasm, src-Family Kinases, Phosphatidylinositol 3-Kinases, Tumor Suppressor Proteins, Cell Line, Tumor, Proto-Oncogene Proteins c-akt, PTEN Phosphohydrolase, Mice, Antibodies, Monoclonal, Humanized

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks